0001217234-26-000038
SEC filingCareDx completed the sale of its Lab Products business to Eurobio for $171.7M and acquired Naveris for $161.8M plus up to $100M earn-out, sharpening focus on U.S. precision medicine and expanding into specialty oncology.
This 8-K filing reports two significant transformative transactions: the divestiture of CareDx's Lab Products business and the acquisition of Naveris, both completed within days of each other. The sale to Eurobio Scientific for $171.7 million in cash sharpens CareDx's strategic focus on its core U.S. Precision Medicine Testing Services and Patient & Digital Solutions, simplifying operations and providing capital for high-growth areas. Concurrently, the acquisition of Naveris for $161.8 million in cash plus up to $100 million in earn-out based on revenue milestones expands CareDx into specialty oncology, a high-growth adjacent market. Naveris's NavDx test, the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD, generated approximately $35 million in revenue in 2025 with over 130,000 tests commercially reported, demonstrating strong adoption and reimbursement. The combined transaction positions CareDx to leverage its commercial platform to scale Naveris's products, with a combined addressable market exceeding $12 billion. Management, led by President and CEO John Hanna, emphasized that these moves align with their growth model of commercializing category-leading, repeat molecular biomarker testing. The financial impact of the Lab Products sale and Naveris acquisition is expected to be detailed in the second quarter 2026 earnings call, with Naveris consolidated into results starting Q3 2026.